Shares of BioMarin Pharmaceutical (BMRN +1.32%) are up more than 40% in the last 12 months, and lately all eyes have been on its experimental Morquio syndrome drug. However, today the orphan drugmaker announced a $10 million deal to acquire Zacharon Pharmaceuticals. In this video, our health care analyst discusses this news and touches on last year's success of some prominent orphan drug companies, including NPS Pharmaceuticals (NASDAQ: NPSP) and Sarepta (SRPT +1.52%).
BioMarin Goes Shopping
By Max Macaluso – Jan 7, 2013 at 4:23PM
NASDAQ: BMRN
BioMarin Pharmaceutical

Market Cap
$10B
Today's Change
(1.32%) $0.70
Current Price
$53.77
Price as of October 21, 2025 at 3:58 PM ET
Orphan drugmaker BioMain takes a small bet on Zacharon pharma
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo